During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
Commentary|Articles|April 23, 2026
FAQ: Insights on On-Body Injector for Anti-CD38 in Multiple Myeloma
Author(s)Jonah Feldman, Sikander Ailawadhi, MD
Fact checked by: Andrea Eleazar, MHS
As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions.
Advertisement
Advertisement
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued an opinion recommending the approval of subcutaneous (SC) administration of isatuximab (Sarclisa).1 Although it is not the first subcutaneous therapy in multiple myeloma, the use of an on-body injector (OBI) in the supporting phase 3 IRAKLIA trial (NCT05405166) gives the topic of subcutaneous administration even greater promise to improve patient convenience.
Related to this article
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Eftilagimod alfa plus pembrolizumab and radiotherapy yielded 81.1% disease-free survival at 12 months in patients with resectable soft tissue sarcoma.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
During a live event, Theresa Medina, MD, and participants discussed how disease site, BRAF status, and prior therapy guide treatment selection in metastatic melanoma.
The FDA has approved the PCR-based OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors for treatment with pembrolizumab.
Advertisement
Advertisement